跳至主要内容
临床试验/ACTRN12617001109392
ACTRN12617001109392已完成未知

An observational study to assess the ability of the thymine loading test to prospectively categorise patients with gastrointestinal or breast cancer who cannot tolerate fluoropyrimidine treatment.

niversity of Auckland0 个研究点目标入组 166 人开始时间: 2017年7月28日最近更新:
适应症

试验速览

阶段
未知
状态
已完成
发起方
入组人数
166

研究概览

简要总结

暂无简介。

研究设计

研究类型
Observational

入排标准

年龄范围
18 Years 至 o limit(—)
性别
All

入选标准

  • Age >18 years.
  • - To receive 5-FU or capecitabine (GI) or capecitabine (mBC) as part of standard care for histologically or cytologically confirmed gastrointestinal (GI) cancer or metastatic breast cancer (mBC); OR
  • - To receive capecitabine as part of standard care for residual disease present at surgery following neoadjuvant chemotherapy for breast cancer
  • - Able to provide written informed consent

排除标准

  • - Pregnant or breast feeding
  • - Concurrent abdomino-pelvic radiation therapy
  • - Irinotecan containing schedules
  • - Prior history of infusional 5-FU or capecitabine

研究者

发起方
niversity of Auckland

相似试验